Obovatol

Obovatol at a Glance

Obovatol is a neolignan from the bark and leaves of Japanese bigleaf magnolia (Magnolia obovata) and houpo (Magnolia officinalis) — the same plants that supply the far better-known magnolol and honokiol. Structurally it belongs to the same bisphenol neolignan family, but its two allyl-phenol units are joined by a diphenyl-ether (C–O–C) bridge rather than the direct carbon–carbon biaryl bond of magnolol and honokiol.

Its research profile is real but entirely preclinical. The most developed line of work is neurological: obovatol reduces microglial neuroinflammation, promotes neurotrophic signalling, and improves memory in rodent Alzheimer’s-type models with an accompanying anti-amyloid signal ^{1,2,3,5Reference 1Li N et al. · 2024Systematic reviewNeolignans in Magnolia officinalis as natural anti-Alzheimer’s disease agents: a systematic reviewView study →Reference 2Choi DY et al. · 2012AnimalObovatol improves cognitive functions in animal models for Alzheimer’s diseaseView study →Reference 3Choi DY et al. · 2012AnimalObovatol attenuates LPS-induced memory impairments in mice via inhibition of NF-κB signaling pathwayView study →Reference 5Ock J et al. · 2010Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulationView study →}. Alongside this sit consistent anti-inflammatory (NF-κB and inflammasome), pro-apoptotic anticancer, antiplatelet/antithrombotic, and rodent anxiolytic findings ^{7,8,9,11Reference 7Kim J et al. · 2019Obovatol inhibits NLRP3, AIM2, and non-canonical inflammasome activationView study →Reference 8Seo JJ et al. · 2007Anxiolytic-like effects of obovatol isolated from Magnolia obovata: involvement of GABA/benzodiazepine receptors complexView study →Reference 9Park ES et al. · 2011AnimalAntiplatelet activity of obovatol, a biphenolic component of Magnolia obovata, in rat arterial thrombosis and rabbit platelet aggregationView study →Reference 11Lee SY et al. · 2009Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaBView study →}.

There are no human trials of obovatol, and almost every study uses the isolated molecule rather than whole magnolia bark — so the honest posture is a promising but early preclinical candidate, not an established therapeutic. Its measured toxicity is low in animals, but it is a potent inhibitor of the drug-metabolising enzyme CYP2C19 in vitro, which is the most concrete safety flag on the molecule ^{18Reference 18Joo J et al. · 2013In vitroIn vitro metabolism of obovatol and its effect on cytochrome P450 enzyme activities in human liver microsomesView study →}.

Obovatol vs. Magnolol & Honokiol

The magnolia neolignans are usually discussed as a trio, but obovatol is chemically distinct from its two famous siblings in a way worth holding onto.

• Magnolol and honokiol are biaryls — two phenol rings joined directly by a carbon–carbon bond (they are positional isomers of each other).
• Obovatol is a diphenyl ether — the two allyl-phenol rings are joined through an oxygen bridge instead, making it a distinct bisphenol scaffold rather than a magnolol isomer.

Functionally the three overlap heavily — all are lipophilic bisphenols that scavenge radicals, suppress NF-κB-driven inflammation, and show pro-apoptotic and neuroactive effects — which is why obovatol keeps appearing in the same anti-Alzheimer’s and anti-inflammatory reviews as the biaryls ^{1Reference 1Li N et al. · 2024Systematic reviewNeolignans in Magnolia officinalis as natural anti-Alzheimer’s disease agents: a systematic reviewView study →}. But obovatol is by far the least-studied and least-abundant of the three: magnolol and honokiol are the standardisation markers of commercial magnolia bark, while obovatol is a minor constituent whose data are thinner and human-untested. Findings for magnolol or honokiol should not be assumed to transfer to obovatol, and vice versa.

What It's Used For

Obovatol’s pharmacology is broad on paper but shallow in evidence tier: many mechanisms, several animal models, no human data, and — apart from a handful of magnolia-bark neuroinflammation studies — the isolated molecule rather than the whole plant. The evidence is best read mechanism-by-mechanism.

Mechanisms

The unifying thread is a lipophilic bisphenol that both scavenges/regulates ROS and suppresses NF-κB — the same chemistry that ties it to magnolol and honokiol. The GABAergic anxiolytic action and CYP2C19 inhibition are the two mechanisms most specific to the molecule’s own data.

Pharmacokinetics

Human PK is uncharacterised — there are no clinical pharmacokinetic data. The best information comes from human liver microsomes, where obovatol is oxidised to two hydroxy-obovatol metabolites (M1/M2) and then conjugated to mono- and di-glucuronides (M3–M6), i.e. it undergoes both CYP-mediated hydroxylation and glucuronidation ^{18Reference 18Joo J et al. · 2013In vitroIn vitro metabolism of obovatol and its effect on cytochrome P450 enzyme activities in human liver microsomesView study →}. The same study found obovatol potently inhibits CYP2C19 (IC50 0.8 µM) — the one hard, reproducible number on the molecule and the basis of its interaction caution ^{18Reference 18Joo J et al. · 2013In vitroIn vitro metabolism of obovatol and its effect on cytochrome P450 enzyme activities in human liver microsomesView study →}. As a lipophilic bisphenol it is presumed to be reasonably membrane-permeant (the neuro-effects imply brain penetration), but oral bioavailability, plasma levels and half-life are unmeasured, which matters because the anticancer effects require tens-of-µM concentrations that may not be reachable systemically from oral dosing.

Clinical Trials

There are no clinical trials of obovatol — the entire evidence base is in-vitro and animal, and human magnolia data belong to whole-bark or magnolol/honokiol-standardised products, not to obovatol as an isolate.

Last checked: July 2026.

Isolate vs. Plant Studies

Obovatol’s evidence is almost entirely for the isolated molecule, not for magnolia bark as consumed. The memory, anxiolytic, antiplatelet and anticancer studies all dose purified obovatol into rodents or cells ^{2,8,9,13Reference 2Choi DY et al. · 2012AnimalObovatol improves cognitive functions in animal models for Alzheimer’s diseaseView study →Reference 8Seo JJ et al. · 2007Anxiolytic-like effects of obovatol isolated from Magnolia obovata: involvement of GABA/benzodiazepine receptors complexView study →Reference 9Park ES et al. · 2011AnimalAntiplatelet activity of obovatol, a biphenolic component of Magnolia obovata, in rat arterial thrombosis and rabbit platelet aggregationView study →Reference 13Zhang L et al. · 2026Obovatol induces apoptosis in breast cancer by downregulating the PI3K/Akt pathwayView study →}; the closest thing to a whole-plant vehicle is the microglial/neuroinflammation work, where obovatol is discussed as an active constituent of Magnolia obovata / Magnoliae Cortex extracts ^{5,21Reference 5Ock J et al. · 2010Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulationView study →Reference 21Yang EJ et al. · 2013Neuroprotective effects of neolignans isolated from Magnoliae Cortex against glutamate-induced apoptotic stimuli in HT22 cellsView study →}. This creates a specific transferability problem: obovatol is a minor neolignan in bark that is standardised to magnolol and honokiol, so its concentration in any real magnolia tea, tincture or supplement is low and unquantified. Effects demonstrated for isolated obovatol therefore cannot be assumed to occur from ordinary magnolia-bark intake, and human magnolia trials (mostly the M. officinalis + Phellodendron blend) say nothing specific about obovatol.

Prevalence in Nature

Obovatol occurs in the bark and leaves of Magnolia obovata (Japanese bigleaf magnolia, hō-no-ki) and the closely related houpo, Magnolia officinalis ^{2,5Reference 2Choi DY et al. · 2012AnimalObovatol improves cognitive functions in animal models for Alzheimer’s diseaseView study →Reference 5Ock J et al. · 2010Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulationView study →}, including M. officinalis var. biloba, whose leaves and bark are a rich source of obovatol-derived dimeric, trimeric and oligomeric neolignans — a sign that obovatol is a biosynthetic building block for larger neolignan structures in these plants ^{14,21Reference 14Liao C et al. · 2024Obovatol inhibits proliferation, invasion and immune escape of hepatocellular carcinoma cells through modulating the JAK/STAT3/PD-L1 axisView study →Reference 21Yang EJ et al. · 2013Neuroprotective effects of neolignans isolated from Magnoliae Cortex against glutamate-induced apoptotic stimuli in HT22 cellsView study →}. Within the genus it belongs to the defining bisphenol neolignan fraction alongside magnolol and honokiol, but it is consistently the minor member of that group: magnolol (~2–11% of dry bark) and honokiol (~1–5%) dominate the neolignan profile, while obovatol’s own content is low and not well quantified in the literature. Precise per-source concentration figures for obovatol are a documented hole (see the gaps tracker), so no comparative content chart is shown here.

Discovery & Synthesis

Obovatol was isolated from Magnolia obovata, the Japanese bigleaf magnolia whose bark (kōboku/hō-no-ki) has a long history in East Asian traditional medicine for inflammatory and digestive complaints — the species also gives the molecule its name. That traditional anti-infective use has a modern echo: obovatol shows antibacterial activity, including disruption of the Salmonella type III secretion system ^{19Reference 19Choi WS et al. · 2017Inhibitory effect of obovatol from Magnolia obovata on the Salmonella type III secretion systemView study →}. It sits in the same phytochemical family as magnolol and honokiol but was characterised later and studied far less; the precise first-isolation date is not well documented in the accessible literature.

Because obovatol is a comparatively simple diphenyl-ether bisphenol, it is amenable to total synthesis, and synthetic and semi-synthetic chemistry — rather than plant extraction — has driven much of its later research. Total synthesis of obovatol and neolignan analogues has been reported in the context of screening for α-glucosidase / α-amylase inhibitors ^{22Reference 22Sciacca C et al. · 2024Synthesis of obovatol and related neolignan analogues as α-glucosidase and α-amylase inhibitorsView study →}, and several derivatives (diacetylated obovatol, Mannich bases, and designated leads such as JJK694, JY0691 and OD 78) have been made to sharpen its antiplatelet, anti-proliferative and anticancer activities ^{10Reference 10Yu JY et al. · 2012Anti-platelet activity of diacetylated obovatol through regulating cyclooxygenase and lipoxygenase activitiesView study →}. This synthetic accessibility, plus its low natural abundance, means research-grade obovatol is typically made or semi-synthesised rather than extracted at scale.

Patents: not yet researched.

Dosage

There is no established human dose — obovatol has never been tested in people. The figures below are preclinical research doses, included for context only:

Note the gap between the low-µM concentrations active on platelets and the tens-of-µM needed for direct cytotoxicity — and that none of these have known human-achievable equivalents, since obovatol’s oral bioavailability is unmeasured. These are doses studied in research and are not a personal recommendation.